Profle of pomalidomide and its potential in the treatment of myelofbrosis

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 549-556

  Gowin, Krisstina L ^a   Mesa, Ruben A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Immunomodulatory; Myelofbrosis; Myeloproliferative neoplasm; Pomalidomide

Indexed keywords

LENALIDOMIDE; PLACEBO; POMALIDOMIDE; PREDNISONE; RUXOLITINIB; THALIDOMIDE;

ANEMIA; BONE MARROW SUPPRESSION; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYTOPENIA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOFIBROSIS; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SEPSIS; SOMNOLENCE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 84928109467     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S69211     Document Type: Review

References (61)

1. Tefferi A. Pathogenesis of myelofbrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520–8530.
2. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofbrosis. Blood. 2000;96(4):1342–1347.
3. Xu M, Bruno E, Chao J, et al. Constitutive mobilization of CD34+ cells into the peripheral blood in idiopathic myelofbrosis may be due to the action of a number of proteases. Blood. 2005;105(11):4508–4515.
4. Tefferi A. Primary myelofbrosis: 2014 update on diagnosis, risk-stratifcation, and management. Am J Hematol. 2014;89(9):915–925.
5. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1): 68–76.
6. Birgegard G. Does anything work for anaemia in myelofbrosis? Best Pract Res Clin Haematol. 2014;27(2):175–185.
7. Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofbrosis based on a study of the International Working Group for Myelofbrosis Research and Treatment. Blood. 2009;113(13): 2895–2901.
8. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofbrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–5270.
9. Tefferi A, Silverstein MN. Recombinant human erythropoietin therapy in patients with myelofbrosis with myeloid metaplasia. Br J Haematol. 1994;86(4):893.
10. Tefferi A, Elliot MA, Yoon SY, et al. Clinical and bone marrow effects of interferon alfa therapy in myelofbrosis with myeloid metaplasia. Blood. 2001;97(6):1896.
11. Hasselbalch HC, Clausen NT, Jensen BA. Successful treatment of anemia in idiopathic myelofbrosis with recombinant human erythropoietin. Am J Hematol. 2002;70(2):92–99.
12. Martinez-Trillos A, Gaya A, Maffoli M, et al. Effcacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofbrosis: results in 40 patients. Ann Hematol. 2010;89(12): 1233–1237.
13. Cervantes F, Mesa R, Barosi G. New and old treatment modalities in primary myelofbrosis. Cancer J. 2007;13(6):377–383.
14. Singh PP, Timucin T, Nagorney DM, Tefferi A. Splenectomy for massive splenomegaly associated with myelofbrosis: outcomes from 63 patients at Mayo Clinic. ASH Annual Meeting Abstracts. 2012;120(21):2848.
15. Pardanani A, Brown P, Neben-Wittich M, Tobin R, Tefferi A. Effective management of accelerated phase myelofbrosis with low-dose splenic radiotherapy. Am J Hematol. 2010;85(9):715–716.
16. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofbrosis. Blood. 2009;113(22):5394–5400.
17. Barosi G, Elliott M, Canepa L, et al. Thalidomide in myelofbrosis with myeloid metaplasia: a pooled-analysis of individual patient data from fve studies. Leuk Lymphoma. 2002;43(12):2301–2307.
18. Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxic-ity in polycythemia vera. Blood. 2008;112(8):3065–3072.
19. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myel-oid metaplasia with myelofbrosis. Cancer Cell. 2005;7(4):387–397.
20. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144–1148.
21. Santos FPS, Verstovsek S. Breakthroughs in myeloproliferative neoplasms. Hematology. 2012;17 Suppl 1:S55–S58.
22. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with rux-olitinib versus best available therapy for myelofbrosis. N Engl J Med. 2012;366(9):787–798.
23. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year effcacy, safety, and survival fndings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofbrosis. Blood. 2013;122(25):4047–4053.
24. Gowin K, Mesa R. Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofbrosis. Expert Opin Investig Drugs. 2013;22(12):1603–1611.
25. Azima H, Arthurs D. Control study of thalidomide (Kevadon), a new hypnotic agent. Am J Psychiatry. 1961;118:554–555.
26. Somers GS. Thalidomide and congenital abnormalities. Lancet. 1962; 1(7235):912–913.
27. D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9): 4082–4085.
28. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalido-mide in refractory multiple myeloma. N Engl J Med. 1999;341(21): 1565–1571.
29. Tefferi A. Serious myeloproliferative reactions associated with the use of thalidomide in myelofbrosis with myeloid metaplasia. Blood. 2000; 96(12):4007.
30. Barosi G, Grossi A, Comotti B, Musto P, Gamba G, Marchetti M. Safety and effcacy of thalidomide in patients with myelofbrosis with myeloid metaplasia. Br J Haematol. 2001;114(1):78–83.
31. Canepa L, Ballerini F, Varaldo R, et al. Thalidomide in agnogenic and secondary myelofbrosis. Br J Haematol. 2001;115(2):313–315.
32. Pozzato G, Zorat F, Nascimben F, Comar C, Kikic F, Festini G. Tha-lidomide therapy in compensated and decompensated myelofbrosis with myeloid metaplasia. Haematologica. 2001;86(7):772–773.
33. Elliott MA, Mesa RA, Li CY, et al. Thalidomide treatment in myelofbro-sis with myeloid metaplasia. Br J Haematol. 2002;117(2):288–296.
34. Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelo-fbrosis with myeloid metaplasia. Blood. 2003;101(7):2534–2541.
35. Marchetti M, Barosi G, Balestri F, et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofbrosis with myeloid metaplasia: a phase II trial. J Clin Oncol. 2004;22(3):424–431.
36. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based drug therapy for myelofbrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79(7):883–889.
37. Silver RT. Myelofbrosis: thalidomide fnds a new disease. Mayo Clin Proc. 2004;79(7):857–858.
38. Strupp C, Germing U, Scherer A, et al. Thalidomide for the treatment of idiopathic myelofbrosis. Eur J Haematol. 2004;72(1):52–57.
39. Abgrall J-F, Guibaud I, Bastie J-N, et al. Thalidomide versus placebo in myeloid metaplasia with myelofbrosis: a prospective, randomized, double-blind, multicenter study. Haematologica. 2006;91(8): 1027–1032.
40. Thomas DA, Giles FJ, Albitar M, et al. Thalidomide therapy for myelo-fbrosis with myeloid metaplasia. Cancer. 2006;106(9):1974–1984.
41. Berrebi A, Feldberg E, Spivak I, Shvidel L. Mini-dose of thalidomide for treatment of primary myelofbrosis. Report of a case with complete reversal of bone marrow fbrosis and splenomegaly. Haematologica. 2007;92(2):e15–e16.
42. Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN. Low-dose thalidomide in myelofibrosis. Haematologica. 2008; 93(7):1100–1101.
43. Koh KR, Janz M, Mapara MY, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005; 105(10):3833–3840.
44. Lentzsch S, LeBlanc R, Podar K, et al. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia. 2003;17(1):41–44.
45. Chamberlain PP, Lopez-Girona A, Miller K, et al. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Nat Struct Mol Biol. 2014;21(9):803–809.
46. Anderson KC, Prince HM. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol. 2005;42(4 Suppl 4):S1–S2.
47. Blade J, Rosinol L, Fernandez de Larrea C. How I treat relapsed myeloma. Blood. January 13, 2015. [Epub ahead of print].
48. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelo-fbrosis with myeloid metaplasia. Blood. 2006;108(4):1158–1164.
49. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofbrosis: cytoge-netic and JAK2V617F molecular remissions. Leukemia. 2007;21(8): 1827–1828.
50. Quintas-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalido-mide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofbrosis. J Clin Oncol. 2009; 27(28):4760–4766.
51. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol. 2008;141(1):41–51.
52. Lacy MQ, Rajkumar SV. Pomalidomide: a new IMiD with remarkable activity in both multiple myeloma and myelofbrosis. Am J Hematol. 2010;85(2):95–96.
53. Tefferi A, Verstovsek S, Barosi G, et al. Pomalidomide is active in the treatment of anemia associated with myelofbrosis. J Clin Oncol. 2009;27(27):4563–4569.
54. Mesa RA, Pardanani AD, Hussein K, et al. Phase 1/-2 study of pomali-domide in myelofbrosis. Am J Hematol. 2010;85(2):129–130.
55. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofbrosis. Leukemia. 2011;25(2):301–304.
56. Begna KH, Pardanani A, Mesa R, et al. Long-term outcome of pomali-domide therapy in myelofbrosis. Am J Hematol. 2012;87(1):66–68.
57. Daver N, Shastri A, Kadia T, et al. Modest activity of pomalidomide in patients with myelofbrosis and signifcant anemia. Leuk Res. 2013; 37(11):1440–1444.
58. Daver N, Shastri A, Kadia T, et al. Phase II study of pomalidomide in combination with prednisone in patients with myelofbrosis and signifcant anemia. Leuk Res. 2014;38(9):1126–1129.
59. Tefferi A, Passamonti F, Barbui G, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-associated myelofbrosis with RBC-transfusion-dependence. Presented at the American Society of Hematology 55th Annual Meeting, December 7–10, 2013, New Orleans, LA, USA.
60. Stefelmann F, Reiter A, et al. A multicenter Phase-Ib/II study of ruxolitinib/pomalidomide combination therapy in patients with primary and secondary myelofbrosis: safety data from the MPNSG-0212 trial. Presented at the American Society of Hematology 56th Annual Meeting, December 6–9, 2014, San Francisco, CA, USA.
61. Verstovsek S. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofbrosis. Postgrad Med. 2013; 125(1):128–135.